Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
SAN DIEGO, Jan. 02, 2018 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the J.P. Morgan 36th Annual Healthcare Conference on Tuesday, Jan. 9, 2018 at 12:00 p.m. PT at the Westin St. Francis in San Francisco.
A webcast of the presentation will be available through the investor section of the AnaptysBio website. Replays of the webcast will be available for 90 days following the events.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, which have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene.
Contact:
Monique Allaire
THRUST Investor Relations
617.895.9511
[email protected]
Chelcie Lister
THRUST Investor Relations
910.777.3049
[email protected]
